Your institution may have access to this item. Find your institution then sign in to continue.
Title
Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
Authors
Parhofer, K G; Birkeland, K I; DeFronzo, R; Del Prato, S; Bhaumik, A; Ptaszynska, A
Abstract
Intervention studies have shown that angiotensin receptor blockers (ARB) may reduce the incidence of type 2 diabetes mellitus. It is currently unclear whether short-term therapy with ARBs affects metabolic parameters.
Publication
International journal of clinical practice, 2010, Vol 64, Issue 2, p160